Related Experiment Video
Updated: Feb 9, 2026

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
Published on: September 12, 2025
SOHO State of the Art Updates and Next Questions | Sequencing Therapies in Relapsed/Refractory Mantle Cell Lymphoma
Jean M Clement1, Craig A Portell1
1Department of Medicine, Division of Hematology/Oncology, University of Virginia, Charlottesville, VA.
Abstract:
Mantle cell lymphoma (MCL) is a rare non-Hodgkin lymphoma that, despite advances in treatment, remains incurable. Clinical courses can range from indolent to aggressive. As understanding of the pathophysiology improves and more targeted therapies shift to the frontline setting, treatment of relapsed and refractory MCL is becoming less defined. This review discusses the evidence of current and emerging treatment strategies for patients with relapsed and refractory MCL, including Bruton tyrosine kinase inhibitor (BTKi) therapies and immunotherapies such as bispecific T-cell engagers and chimeric antigen receptor T-cells.
Related Concept Videos
Gene Therapy
Cis-regulatory Sequences
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Sequences
Group Therapy
Sanger Sequencing

